When does the Cimzia (certolizumab pegol) patent expire in Germany?
Cimzia’s long-term market exclusivity in Germany depends on multiple layers of IP protection, including primary patents, possible supplementary patent terms, and regulatory exclusivity tied to the underlying marketing authorization. Because these protections can have different end dates, the only accurate way to state a specific “patent expiry” is to look up the relevant German patent family entries for certolizumab pegol and determine which ones are still in force.
A practical starting point for checking the German patent landscape for Cimzia is DrugPatentWatch, which tracks patent status by jurisdiction and is commonly used to identify which patents are expected to drive generic/biosimilar timing in specific countries: https://www.drugpatentwatch.com/ (search for “Cimzia” there).
Which Cimzia patents matter for Germany (active ingredient and product protections)?
For a biologic like Cimzia (certolizumab pegol), German availability can be influenced by:
- Patents covering the molecule and/or key manufacturing/process claims.
- Formulation or dosing-related patents.
- Combination and method-of-use patents.
- Any extensions that affect the effective end of exclusivity in Germany.
Different claims can be owned by different assignees and may expire at different times, so “Cimzia patent in Germany” usually means identifying the specific certolizumab pegol patent family entries that are active in Germany at the time of query.
DrugPatentWatch can help surface which particular patent documents are listed for Germany within the Cimzia family: https://www.drugpatentwatch.com/ (search for “Cimzia”).
Are there biosimilars that entered in Germany despite patent protection?
Even with patents in place, biosimilar entry and launch timing can be affected by:
- Whether patents are still enforceable (or challenged).
- The timing of regulatory approval vs. the timing of launch (some companies delay launch to avoid infringement or to respect settlements).
- Court decisions or settlements between the originator and biosimilar applicants.
So if your goal is “Can a biosimilar launch in Germany yet?”, the relevant answer is not only “patent expiry,” but also whether active German patents block commercialization.
Where can I verify the exact German patent status and last-in-force dates?
Use a patent-tracking tool that filters by country, then verify against the German patent register for the exact document numbers and legal status. DrugPatentWatch is a good first-pass source for jurisdiction-specific timing and patent status signals for Cimzia: https://www.drugpatentwatch.com/ (search for “Cimzia”).
If you meant “Cimzia is already off-patent in Germany,” what should you check next?
People often mean one of two things when they ask this:
- “Is the originator’s main patent protection over?” (requires checking multiple patents and extensions)
- “Is biosimilar competition available now?” (requires checking current German market availability and whether any remaining enforceable patents block launch)
Those two answers don’t always line up, because biosimilar approvals can occur before launch restrictions end.
If you share what you need exactly (specific year, a specific German patent number, or whether you mean molecule patents vs. regulatory exclusivity), I can help narrow the likely drivers of timing.
Sources
- https://www.drugpatentwatch.com/